BioCentury | Aug 31, 2018
Financial News

Biosimilars company Mabpharm sets sights on Hong Kong IPO

...and all have held managerial roles at Mabpharm subsidiaries Taizhou Mabtech Biotechnology Ltd. and Taizhou Mabtech...
BioCentury | Aug 22, 2018
Financial News

Biosimilars company Mabpharm sets sights on Hong Kong IPO

...and all have held managerial roles at Mabpharm subsidiaries Taizhou Mabtech Biotechnology Ltd. and Taizhou Mabtech...
BioCentury | Aug 15, 2016
Finance

Serving returns

...III Sorrento Therapeutics Inc. (NASDAQ:SRNE) Four biosimilar mAbs for cancer and autoimmune indications licensed from Mabtech Ltd....
BioCentury | Jan 25, 2016
Clinical News

STI-001: Phase III data

...irinotecan alone. Mabtech plans to submit a regulatory application in China for STI-001. Last year, Mabtech...
...biosimilar mAbs, including STI-001, in North America, Europe and Japan (see BioCentury, Sept. 7, 2015). Mabtech Ltd....
BioCentury | Jan 25, 2016
Clinical News

STI-002: Phase III data

...Remicade infliximab. Mabtech plans to submit a regulatory application in China for STI-002. Last year, Mabtech...
...biosimilar mAbs, including STI-002, in North America, Europe and Japan (see BioCentury, Sept. 7, 2015). Mabtech Ltd....
BioCentury | Sep 7, 2015
Company News

Mabtech, Sorrento deal

...review in China. Sorrento did not respond to inquiries, and Mabtech could not be reached. Mabtech Ltd....
BioCentury | Aug 22, 2005
Emerging Company Profile

Corporate Profile

...Corporate partners: NA Employees: 24 Funds raised: £10 million ($18.6 million) Investors: Prelude Ventures; Quester; Mabtech...
BioCentury | Mar 18, 2002
Company News

Seattle Genetics, Mabtech AB deal

...with its antibody-drug conjugate (ADC) technology. Under a 1998 deal, SGEN licensed rights to a Mabtech...
...companies expect to start clinical testing later this year. Seattle Genetics Inc. (SGEN), Bothell, Wash. Mabtech...
BioCentury | Mar 14, 2002
Company News

Seattle Genetics, Mabtech cancer MAb deal

...with its antibody-drug conjugate (ADC) technology. Under a 1998 deal, SGEN licensed rights to a Mabtech...
Items per page:
1 - 9 of 9
BioCentury | Aug 31, 2018
Financial News

Biosimilars company Mabpharm sets sights on Hong Kong IPO

...and all have held managerial roles at Mabpharm subsidiaries Taizhou Mabtech Biotechnology Ltd. and Taizhou Mabtech...
BioCentury | Aug 22, 2018
Financial News

Biosimilars company Mabpharm sets sights on Hong Kong IPO

...and all have held managerial roles at Mabpharm subsidiaries Taizhou Mabtech Biotechnology Ltd. and Taizhou Mabtech...
BioCentury | Aug 15, 2016
Finance

Serving returns

...III Sorrento Therapeutics Inc. (NASDAQ:SRNE) Four biosimilar mAbs for cancer and autoimmune indications licensed from Mabtech Ltd....
BioCentury | Jan 25, 2016
Clinical News

STI-001: Phase III data

...irinotecan alone. Mabtech plans to submit a regulatory application in China for STI-001. Last year, Mabtech...
...biosimilar mAbs, including STI-001, in North America, Europe and Japan (see BioCentury, Sept. 7, 2015). Mabtech Ltd....
BioCentury | Jan 25, 2016
Clinical News

STI-002: Phase III data

...Remicade infliximab. Mabtech plans to submit a regulatory application in China for STI-002. Last year, Mabtech...
...biosimilar mAbs, including STI-002, in North America, Europe and Japan (see BioCentury, Sept. 7, 2015). Mabtech Ltd....
BioCentury | Sep 7, 2015
Company News

Mabtech, Sorrento deal

...review in China. Sorrento did not respond to inquiries, and Mabtech could not be reached. Mabtech Ltd....
BioCentury | Aug 22, 2005
Emerging Company Profile

Corporate Profile

...Corporate partners: NA Employees: 24 Funds raised: £10 million ($18.6 million) Investors: Prelude Ventures; Quester; Mabtech...
BioCentury | Mar 18, 2002
Company News

Seattle Genetics, Mabtech AB deal

...with its antibody-drug conjugate (ADC) technology. Under a 1998 deal, SGEN licensed rights to a Mabtech...
...companies expect to start clinical testing later this year. Seattle Genetics Inc. (SGEN), Bothell, Wash. Mabtech...
BioCentury | Mar 14, 2002
Company News

Seattle Genetics, Mabtech cancer MAb deal

...with its antibody-drug conjugate (ADC) technology. Under a 1998 deal, SGEN licensed rights to a Mabtech...
Items per page:
1 - 9 of 9